Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

Pfizer’s decision to offload $3.05 billion worth of shares in Haleon is a strategic move driven by shifting priorities in a ...

It wants to get ahead of competitors such as BMS, Merck, Pfizer ... The interaction with GSK goes deeper, with Novartis and GSK announcing a merger of their OTC divisions to create a new joint ...

Pfizer is looking to sell about 700 million ordinary shares in Haleon, its bookrunner J.P. Morgan said on Tuesday, lowering ...

The sale represents nearly 7.7% of the issued share capital of Haleon, which was created by the merger of GSK (GSK.L), opens new tab and Pfizer's consumer healthcare businesses in 2019.

Pfizer and GSK vaccines will now be required to carry warnings that they may be tied to an increased risk of a rare neurological side effect. © 2024 Fortune Media IP ...

GSK's $1 billion acquisition of IDRx includes IDRX-42, a precision therapy for GIST. Phase 1/1b trial shows 53% ORR in early treatment stages.

On 16 January 2025, Mr Justice Mellor delivered a judgment in the High Court concerning a patent dispute between Pfizer Limited and GlaxoSmithKline Biologicals S.A along with ID Biomedical Corporation ...

GSK (GSK) and Pfizer (PFE) vaccines for respiratory syncytial virus, or RSV, will carry warnings that they can increase the risk of developing a rare neurological disorder, Reuters writes.

GSK and Pfizer's respiratory syncytial virus (RSV) vaccines will carry warnings that they can increase the risk of developing a rare neurological disorder, the U.S. Food Drug Administration said on ...

Pfizer will lower its stake in Haleon from 15 percent to about 7.3% by selling shares worth 2.50 billion pounds ($3.05 ...